Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom

NEW YORK, June 13, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.

Johnson & Johnson Analyst Notes
On June 4, 2014, Johnson & Johnson reported that its company, Janssen-Cilag International NV (Janssen), announced that the European Commission (EC) has approved the use of SYLVANT® (siltuximab) for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative. According to the Company, the approval was based on the results of MCD2001 Pivotal Study and follows the accelerated assessment and recommendation from the CHMP to approve SYLVANT®. Commenting on the approval, Jane Griffiths, Company Group Chairman of Janssen EMEA stated, "As the first company with an approved medicine to treat MCD in Europe, we are very proud to be able to offer an effective treatment option for eligible patients with this rare and challenging disease and further demonstrate our commitment to patients." The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/JNJ/report.pdf

Furiex Pharmaceuticals, Inc. Analyst Notes
On June 10, 2014, Furiex Pharmaceuticals, Inc.'s (Furiex Pharmaceuticals) stock went down by 0.04%, closing at $105.26. For the past three day trading period, the Company's stock went up by 0.49% compared to the Nasdaq Composite which increased by 0.97% during the same trading session. The full analyst notes on Furiex Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/FURX/report.pdf

Select Medical Holdings Corporation Analyst Notes
On June 10, 2014, Select Medical Holdings Corporation (Select Medical) reported that the Company, along with Cleveland Clinic, finalized an agreement to form a joint venture to improve inpatient rehabilitation services in Northeast Ohio and improve access for patients with complex rehab needs. The Company stated that as part of the joint venture, Cleveland Clinic and Select Medical will expand services on Cleveland's West Side by building a new 60-bed adult inpatient rehabilitation hospital in Avon, Ohio. The companies also entered into a management agreement to enhance operations in existing Cleveland Clinic rehabilitation facilities, effective August 1, 2014. Select Medical added that the venture will also establish a residency program for physicians in physical medicine and rehabilitation. David S. Chernow, Company President and CEO, stated, "Through a shared commitment to delivering the best possible patient experience, I know that we can build something truly special in the post-acute care space." The full analyst notes on Select Medical are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/SEM/report.pdf

CTI BioPharma Corp. Analyst Notes
On May 30, 2014, CTI BioPharma Corp. (CTI) announced the Company's corporate name change, from Cell Therapeutics, Inc. to CTI BioPharma Corp., effective May 30, 2014. The Company added that its common stock will continue to trade under the current ticker symbol CTIC. Commenting on the name change, James A. Bianco, M.D., President, CEO of CTI stated, "The rebranding from Cell Therapeutics to CTI BioPharma comes at a defining moment in our company's history and better reflects who we are today and our aspirations for becoming a leader in developing therapies for patients with blood-related cancers. Currently, we have a growing commercial presence in Europe for PIXUVRI® (pixantrone) for patients with relapsed aggressive B-cell non-Hodgkin lymphoma, and a promising late-stage pipeline that includes a Phase 3 program for pacritinib, a novel JAK2/FLT3 inhibitor, for patients with myelofibrosis." The full analyst notes on CTI are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/CTIC/report.pdf

Hill-Rom Holdings, Inc. Analyst Notes
On June 6, 2014, Hill-Rom Holdings, Inc. (Hill-Rom) announced the Company's new partnership with Ecolab®. According to the Company, the partnership aims to focus on the Hill-Rom® Hand Hygiene Compliance Solution, which integrates products and technologies from both companies. Commenting on the partnership, Adam McMullin, Vice President and General Manager, Hill-Rom® Clinical Workflow Solutions, stated, "The Hill-Rom Hand Hygiene Compliance Solution directly addresses the challenges hospitals are facing with respect to HAIs, as well as responding to regulatory requirements. The Hill-Rom Hand Hygiene Compliance Solution is a great example of our technology platform, which is designed to automate the clinical environment, help improve productivity and safety, and enhance the patient experience." The full analyst notes on Hill-Rom are available to download free of charge at:

http://www.analystsreview.com/Jun-13-2014/HRC/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review